Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

Brigitte Dréno(Inserm), James Larkin(Trinity College Dublin), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grant A. McArthur(The University of Melbourne), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Daniil Stroyakovskiy(Shikoku Cancer Center), L. Thomas, Antoni Ribas(University of California, Los Angeles), Erica Park, Anna Maria Di Giacomo(University of Siena), Jessie J. Hsu, Isabelle Rooney, Victoria Atkinson(Greenslopes Private Hospital), Claus Garbe(University Children's Hospital Tübingen)

Journal of Clinical Oncology

May 20, 2018

Cited by 27

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Investigation|2017|3.9k

|New England Journal of Medicine|2019|3.7k

Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with <i>BRAF</i><sup>V600</sup> mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.